Norris David A
Department of Dermatology, University of Colorado School of Medicine, University of Colorado Denver, Aurora, Colorado, USA.
J Investig Dermatol Symp Proc. 2018 Jan;19(1):S1-S2. doi: 10.1016/j.jisp.2017.10.011.
During its 25th anniversary year, the National Alopecia Areata Foundation (NAAF) undertook a project to completely re-evaluate their research program and to help focus and direct future directions of alopecia areata (AA) research to better meet the goals of individuals with and the scientists working to discover mechanisms of disease and better treatments for AA. This project was embodied in five research summits in 2008, 2009, 2010, 2012, and 2014 as part of the NAAF's main strategic initiative, the Alopecia Areata Treatment Development Program, to accelerate progress toward a viable treatment. The sixth summit, "Building and Crossing the Translational Bridge," was held in 2016 and highlighted strong clinical data on the efficacy of topical and oral JAK inhibitors in mouse models and human AA. The advances discussed in this most recent summit provide real hope for a reliable and relatively safe treatment for AA. This work validates the last 10 years of research translating basic research of AA into new treatments based on the firm foundation of modern immunologic and genetic research.
在成立25周年之际，全国斑秃基金会（NAAF）开展了一个项目，全面重新评估其研究计划，并帮助聚焦和指引斑秃（AA）研究的未来方向，以更好地实现患者以及致力于探索疾病机制和寻求更好的AA治疗方法的科学家们的目标。该项目体现在2008年、2009年、2010年、2012年和2014年举办的五次研究峰会上，作为NAAF主要战略举措“斑秃治疗开发计划”的一部分，以加速实现可行治疗方法的进展。第六届峰会“搭建并跨越转化桥梁”于2016年举行，会上强调了局部和口服JAK抑制剂在小鼠模型和人类斑秃中的疗效的有力临床数据。最近这次峰会上讨论的进展为可靠且相对安全的斑秃治疗带来了真正的希望。这项工作证实了过去十年基于现代免疫学和遗传学研究的坚实基础，将斑秃基础研究转化为新治疗方法的研究成果。
